Oncology Account Manager - Minneapolis

• Achieve the assigned sales objective for the territory

• Attain the designated goals for calls on appropriate healthcare professionals to communicate balanced, accurate, and complete information on Kura’s FDA approved products

• Develops and implements a territory business plan to meet customer needs and achieve goals

• Navigate through complex external/customer organizational structures including hospitals, IDNs, GPOs and healthcare communities while aligning with cross-functional commercial partners

• Demonstrate completion of administrative requirements including budget management, expense reports management, CRM call reporting and synchronization, etc. within timelines and company guidelines

• Demonstrates a deep understanding of healthcare professionals (HCP) and account needs, effectively utilizing this knowledge to strategically promote and expand the use of assigned products

• Operate the territory within the assigned expense budget and demonstrates fiscal responsibility

• Comply with all federal/state/local laws, regulations and guidelines including but not limited to the PhRMA Code on Interactions with Healthcare Professionals as well as complying with all Kura standards and policies relating to all job activities

• Successful completion and ongoing updates of all aspects of training including but not limited to product knowledge, disease state, market, selling skills and compliance

• Assists in the identification and resolution of issues and opportunities while communicating proactively to marketing and sales management

• Develops and consistently demonstrates an expert understanding of HCP and Account needs to appropriately expand use of assigned product. JOB SPECIFICATIONS:

• Undergraduate degree required, ideally in business/marketing/healthcare/life science areas of concentration

• 6+ years of successful pharmaceutical/biotech sales experience with 3+ in the oncology/hematology and/or rare disease markets, preferably with oral therapeutic selling experience

• Management of large territories that includes periodic overnight travel

• Occasionally work evenings and weekends as needed for conferences

• Excellent written and oral communication skills

• Strong computer skills, notably WORD, EXCEL and POWER POINT

The base range for this role is $205,000 to $230,000 per year with a target IC of 60k. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.

#LI-RM1

Kura’s Values that are used for candidate selection and performance assessments:

• We work as one for patients
• We are goal-focused and deliver with excellence
• We are science-driven courageous innovators
• We strive to bring out the best in each other and ourselves

The Kura Package

• Career advancement/ development opportunities
• Competitive comp package
• Bonus
• 401K + Employer contributions
• Generous stock options
• ESPP Plan
• 20 days of PTO to start
• 18 Holidays  (Including Summer & Winter Break)
• Generous Benefits Package with a variety of plans available with a substantial employer match
• Paid Paternity/Maternity Leave
• In-Office Catered lunches
• Home Office Setup
• Lifestyle Spending Stipend
• Commuter Stipend (Boston Office)
• Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more! Kura Oncology is a commercial-stage biopharmaceutical company committed to discovering and developing innovative precision medicines to help patients with cancer lead better, longer lives. Through our deep understanding of cancer biology and decades of experience in precision oncology, we are studying the underlying causes of treatment resistance. This enables us to design smart combination regimens with other cancer therapies to target tumors from multiple directions, with the goal of improving long-term clinical benefit. Kura developed and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn. If you are a California resident, please see the attached Privacy Notice CA Privacy Notice